OneSource Specialty Pharma Q2 FY26 Results: Turnaround to Profit

Negative Operating CashflowEbitda Margin ExpansionExceptional ItemResults View source PDF Explain this filing

ONESOURCE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.0%Reaction day

₹1750.00

prior close

₹1781.80

announcement price

After-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)+0.7%-0.7% vs market

Pharmaceuticals peers, median of 157sector+0.8%-0.8% vs sector

On the reaction day the stock moved 0.7 pts less than Nifty Smallcap 250 and 0.8 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.4

10m

-0.6

15m

+0.1

30m

+0.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.0+0.7-0.7+0.8-0.8

Next day

-1.3+0.3-1.6+0.5-1.8

-1.2+0.5-1.7+0.4-1.6

+0.0+1.2-1.2+0.6-0.6

-1.9+0.2-2.1-0.1-1.8

-2.7-0.3-2.5-0.6-2.2

-7.0-1.6-5.4-1.2-5.8

15d

-5.6-2.2-3.4-1.8-3.8

-7.8-3.5-4.3-2.6-5.3

-1.7-5.3+3.5-5.4+3.7

-30.3-4.4-25.9-5.7-24.6

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

OneSource Specialty Pharma Q2 FY26 consolidated revenue at Rs. 375.76 crore, up 12.5% YoY. PAT swung to Rs. 10.49 crore profit from Rs. 42.08 crore loss YoY. H1 revenue rose 12.2% to Rs. 703.03 crore with PAT of Rs. 10.30 crore vs Rs. 47.62 crore loss prior year. Operating cash flow stayed negative at Rs. 39.92 crore though improved from Rs. 124.45 crore outflow. Board approved amalgamation with Brooks Steriscience and related entities. Deloitte issued unmodified review.

Likely market impact

Turnaround to profit with revenue growth signals recovery, but negative operating cash flow and pending amalgamation scheme warrant close watch.